about
Synthesis, characterization, and remarkable biological properties of cyclodextrins bearing guanidinoalkylamino and aminoalkylamino groups on their primary side.A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressivThe future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injuryA novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD.Gene expression profile associated with oncogenic ras-induced senescence, cell death, and transforming properties in human cells.Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line.Post-mitotic, differentiated myotubes efficiently produce retroviral vector from hybrid adeno-retrovirus templates.Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE.Adenovirus-based targeting in myoblasts is hampered by nonhomologous vector integration.Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle.FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death.The combination of bcl-2 expression and NGF-deprivation facilitates the selective destruction of BAD protein in living sympathetic neurons.Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha- RAS -transformed human colon cellsIn vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles
P50
Q33326526-AFEA6964-20D3-4F32-BC68-E2D905ABA9C0Q33568960-59C0DF61-A14E-4E07-B6A4-4F4A679CB867Q34836038-6A798F59-91C1-46DF-ADB6-93E55DC25A3EQ36545939-4756DCD8-4F80-4781-8D22-E563D8C0B9CDQ36736482-457CB3CA-09A1-4E19-BAF3-1EC6ABAEACBDQ39780398-0E095146-FAE2-44BD-AFA3-BAC8A1E1CEC7Q40375558-CE9BBD82-652A-4193-A34C-54BAD5B2FD7DQ40769259-48A08D96-DF48-4D59-83F5-373E2A9A16C9Q43843334-7838CBBD-67F3-47EE-AC91-2EDF6267DC06Q43899428-1DFB34B0-D597-43EA-95FA-0E0F1F626B53Q45887463-A7987991-4DF3-4543-B225-82E93AB596D0Q48130829-B1D468F8-172E-4543-9D32-DD2972379D81Q48563119-505FF9C8-650C-4669-827D-21BDA6C2B02BQ56780316-9F1789F3-B787-4EC2-80CE-E8696C33B7E2Q79634361-B8778174-E627-4186-9A6A-16B4CEFCF923
P50
description
genetic researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael L Roberts
@ast
Michael L Roberts
@en
Michael L Roberts
@es
Michael L Roberts
@nl
type
label
Michael L Roberts
@ast
Michael L Roberts
@en
Michael L Roberts
@es
Michael L Roberts
@nl
altLabel
Michael L. Roberts
@en
Michael Roberts
@en
Mike Roberts
@en
prefLabel
Michael L Roberts
@ast
Michael L Roberts
@en
Michael L Roberts
@es
Michael L Roberts
@nl
P106
P31
P496
0000-0001-7387-1155